Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer using its Helicon™ peptide platform to drug historically ...
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer ...
SpringWorks Therapeutics, a subsidiary of German drugmaker Merck KGaA (MRK: DE), today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing ...
Varegacestat reduced the risk of disease progression or death by 84% compared with placebo in patients with progressing desmoid tumors. Topline data were announced from a phase 3 trial evaluating ...
(RTTNews) - Immunome, Inc. (IMNM) is scheduled to report topline Phase 3 results of its lead drug candidate, Varegacestat, in desmoid tumors, dubbed RINGSIDE trial, today. Desmoid tumors are rare, ...
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced positive topline results from the global ...
Registrational trial met primary endpoint, with varegacestat significantly improving progression-free survival vs. placebo (hazard ratio = 0.16, p<0.0001) Trial also met all key secondary endpoints, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results